Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Last updated: February 26, 2025
Sponsor: Stanford University
Overall Status: Active - Recruiting

Phase

2

Condition

Gliomas

Brain Cancer

Cancer/tumors

Treatment

[6,6-²H₂]-Glucose

Clinical Study ID

NCT06855628
IRB-77846
R01CA277832-02
  • Ages > 18
  • All Genders

Study Summary

The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11)

  • Women of childbearing potential must have a negative pregnancy test

  • Ability to understand and the willingness to provide written informed consent.

Exclusion

Exclusion Criteria:

  • Refuse to have an IV

  • Allergy to MRI contrasts

  • Diabetic patients who are taking insulin

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: [6,6-²H₂]-Glucose
Phase: 2
Study Start date:
January 30, 2025
Estimated Completion Date:
February 29, 2028

Connect with a study center

  • Stanford University

    Palo Alto, California 94305
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.